The Melanocortin System and α-MSH Context
The melanocortin system comprises five G protein-coupled receptors (MC1R–MC5R) activated by peptides derived from the POMC (proopiomelanocortin) precursor. Among these, α-MSH (α-melanocyte-stimulating hormone, 13 amino acids: Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) is the highest-affinity endogenous agonist for MC1R, MC3R, and MC4R. MC1R is expressed predominantly in melanocytes and immune system cells — monocytes, macrophages, neutrophils, dendritic cells — where its activation negatively modulates the inflammatory response through cAMP/PKA signaling that antagonizes NF-κB and AP-1 pathways. KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-MSH, corresponding to residues 11–13 of the mature peptide. Despite its small size, KPV retains documented anti-inflammatory activity across multiple in vitro and in vivo models, generating interest as a research tool for melanocortin system pharmacology.
MC1R Pharmacology: Binding, Signaling, and Selectivity
MC1R is a 7-transmembrane domain receptor coupled primarily to Gs protein. Agonist binding produces adenylate cyclase activation, intracellular cAMP elevation, and PKA (cAMP-dependent protein kinase) activation. PKA phosphorylates and activates CREB (cAMP response element-binding protein), a transcription factor that induces expression of CRE-containing genes — including anti-inflammatory genes — and antagonizes NF-κB pro-inflammatory signaling. KPV affinity for recombinant human MC1R is considerably lower than full-length α-MSH: Ki for MC1R of approximately 200–500 nM for KPV versus 1–5 nM for α-MSH, by radioligand competition binding with [125I]-NDP-α-MSH. MC1R can also signal through the β-arrestin pathway (uncoupled from Gs), with functional consequences for receptor internalization and inflammatory response modulation distinct from classical Gs/cAMP signaling. KPV also shows activity on MC3R with low selectivity versus MC1R; exclusive attribution of its effects to MC1R requires confirmation with selective antagonists such as MSG606 or AgRP(83-132).
NF-κB Inhibition and Pro-Inflammatory Cytokine Production
In LPS-stimulated RAW264.7 macrophages (1 μg/mL LPS, 6h), KPV at concentrations of 10–100 nM produces: reduction of IκBα phosphorylation at Ser32 (Western blot with anti-pIκBα, normalized to total IκBα) by 30–50% over LPS-treated cells without KPV (p<0.01); reduction of nuclear translocation of NF-κB p65 subunit (EMSA or p65-DNA binding assay) by 35–55%; reduction of TNF-α production in supernatant (ELISA) by 30–45%; reduction of IL-1β production by 35–50%; and reduction of IL-6 production by 25–40% (p<0.05–0.01 depending on assay). These effects are reproducible in C57BL/6J mouse bone marrow-derived macrophages (BMDM) with similar magnitude profiles. In PMA-differentiated THP-1 monocytes, KPV at 100 nM produces TNF-α reduction of 25–40% over LPS-stimulated (p<0.05).
In Vivo Inflammation Models
In DSS-induced colitis in C57BL/6J mice (3% DSS in drinking water for 7 days), KPV at 100–300 μg/kg/day IP produces: reduction of the disease activity index (DAI, composite of weight loss, stool consistency, and rectal bleeding scores) by 30–40% versus control at day 7 (p<0.05); reduction of TNF-α levels in colon homogenate by 35–50% (p<0.01); reduction of histological inflammation score (0–4 scale by H&E) by 25–35% (p<0.05); and greater colon length (colon shortening is a chronic inflammation marker, partially recovered in KPV-treated groups). In TNBS-induced colitis (intrarectal trinitrobenzenesulfonic acid, 100 mg/kg in 50% ethanol), KPV at 50–100 μg/kg IP reduces spleen mass index (secondary splenomegaly from chronic inflammation) by 20–30% and reduces myeloperoxidase (MPO) in colon homogenate by 30–45% (p<0.05).
Stability, Pharmacokinetics, and Quality Considerations
KPV, as a tripeptide (MW ~341 Da), has a very short plasma half-life in unprotected plasma: LC-MS/MS estimates suggest t½ of 5–15 minutes in rat plasma at 37°C due to plasma peptidase activity. This in vitro instability is an important methodological consideration: effective concentration in cell cultures may differ from nominal concentration if the material degrades in culture medium before acting on cells. Storage as lyophilizate at -20°C and reconstitution in cold PBS with immediate use are standard conditions. For reproducible research, KPV must meet: ≥98% purity by HPLC-UV at 214 nm; identity confirmed by ESI-MS with [M+H]+ mass of 342.2 ± 0.1 Da; endotoxins <1 EU/mg by LAL assay; counterion form specified (acetate). Alpha Nordisk supplies KPV under lot A26Q2KPV0149 with CoA verifiable at alphanordisk.com/verify including chromatogram, mass spectrum, and endotoxin result. For research and laboratory use. Not for unsupervised human consumption.